# Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

> **NCT01345006** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Institute for Regenerative Medicine** · enrollment: 13 (actual)

## Conditions studied

- Stargardt's Macular Dystrophy

## Interventions

- **BIOLOGICAL:** MA09-hRPE

## Key facts

- **NCT ID:** NCT01345006
- **Lead sponsor:** Astellas Institute for Regenerative Medicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-16
- **Primary completion:** 2015-08-10
- **Final completion:** 2015-08-10
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345006, "Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01345006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*